Compare NNNN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | ATAI |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Germany | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2025 | 2021 |
| Metric | NNNN | ATAI |
|---|---|---|
| Price | $27.70 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 26.9K | ★ 3.6M |
| Earning Date | 04-28-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $8,185,146.00 | $3,018,000.00 |
| Revenue This Year | N/A | $943.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $534.57 | ★ N/A |
| Revenue Growth | 21.95 | ★ 811.78 |
| 52 Week Low | $5.18 | $1.15 |
| 52 Week High | $55.65 | $6.75 |
| Indicator | NNNN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 44.63 |
| Support Level | $26.89 | $4.25 |
| Resistance Level | $44.73 | $4.63 |
| Average True Range (ATR) | 5.78 | 0.22 |
| MACD | -0.21 | 0.08 |
| Stochastic Oscillator | 29.62 | 52.91 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.